ENDV ENDONOVO THERAPEUTICS, INC.
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 1528172 · Fiscal year ends 12/31
Financial factors as of 2023-09-30 (2023Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,699.9%
TTM net income YoY-40.0%
TTM EPS YoY—
Revenue 3-yr CAGR-5.5%
Net income 3-yr CAGR—
Margins
Gross margin96.2%
Operating margin-1,023.2%
Net margin-1,722.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-388.5%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets2,914.6%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.14x
Accruals ratio-333.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2023Q32023-09-30 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 | 2022Q32022-09-30 | 2022Q22022-06-30 | 2022Q12022-03-31 | 2021Q4*2021-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1,520 | $45,200 | $87,540 | $121,463 | $10,960 | $650 | $2,282 | $316 |
| Cost of revenue | $827 | $0 | $3,996 | $4,866 | $4,027 | $383 | $714 | $8,861 |
| Gross profit | $693 | $45,200 | $83,544 | $116,597 | $6,933 | $267 | $1,568 | -$8,545 |
| R&D expense | — | — | — | — | — | — | — | $0 |
| Operating income | -$472,797 | -$1.13M | -$529,290 | -$483,051 | -$496,778 | -$1.80M | -$485,762 | -$373,794 |
| Pretax income | -$766,170 | $2.06M | $7.23M | -$12.93M | -$603,360 | -$2.53M | -$2.41M | $2.40M |
| Net income | -$766,170 | $2.06M | $7.23M | -$12.93M | -$603,360 | -$2.53M | -$2.41M | $2.40M |
| EBITDA | -$311,069 | — | — | -$321,323 | -$335,050 | -$1.64M | -$324,034 | -$212,066 |
| EPS (basic) | -0.00 | 0.00 | 0.03 | — | 0.00 | -0.02 | -0.03 | — |
| EPS (diluted) | 0.00 | -0.01 | 0.00 | — | 0.00 | -0.02 | -0.03 | — |
| Weighted avg. shares (diluted) | 1.35B | 1.35B | 1.74B | — | 153.60M | 134.36M | 79.01M | — |
| Banking | ||||||||
| Net interest income | -$285,892 | -$312,869 | -$309,380 | -$309,326 | -$338,571 | -$337,536 | -$336,142 | -$227,354 |
| Balance sheet | ||||||||
| Cash & equivalents | $0 | $32,602 | $10,942 | $98 | $23,139 | $0 | $59,982 | $85,936 |
| Receivables | — | — | $3,120 | — | $944 | $945 | $945 | $944 |
| Current assets | $35,504 | $72,833 | $95,172 | $15,822 | $24,083 | $5,945 | $64,427 | $94,855 |
| Intangibles | $780,260 | $941,988 | $1.10M | $1.27M | $1.43M | $1.59M | $1.75M | $1.91M |
| Total assets | $815,764 | $1.01M | $1.20M | $1.28M | $1.45M | $1.59M | $1.82M | $2.01M |
| Current liabilities | $23.70M | $23.14M | $25.49M | $33.38M | $20.98M | $20.68M | $19.77M | $17.70M |
| Long-term debt | $7.09M | $7.05M | $6.90M | $7.15M | $7.27M | $7.41M | $7.35M | $7.26M |
| Total debt | $7.09M | $7.05M | $6.90M | $7.15M | $7.27M | $7.41M | $7.35M | $7.26M |
| Total liabilities | $23.78M | $23.22M | $25.57M | $33.46M | $21.06M | $20.75M | $19.85M | $17.78M |
| Shareholders' equity | -$22.96M | -$22.41M | -$24.37M | -$32.18M | -$19.61M | -$19.16M | -$18.04M | -$15.77M |
| Net debt | $7.09M | $7.02M | $6.89M | $7.15M | $7.25M | $7.41M | $7.29M | $7.17M |
| Shares outstanding | 318.75M | 278.80M | 270.29M | 213.23M | 159.23M | 150.43M | 81.33M | 74.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$65,367 | -$165,840 | -$173,156 | -$225,541 | -$123,861 | -$206,482 | -$122,954 | -$391,296 |
| Financing cash flow | $32,765 | $187,500 | $184,000 | $202,500 | $147,000 | $146,500 | $97,000 | $471,500 |
| Depreciation & amortization | $161,728 | — | — | $161,728 | $161,728 | $161,728 | $161,728 | $161,728 |
| Stock-based compensation | $0 | $3,440 | $2,560 | $45,000 | $0 | — | — | -$61,000 |
Free plan shows the latest 8 periods; Pro shows all 49 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.